Corporate | 30 April 2008 09:45
ECKERT & ZIEGLER Strahlen- und Medizintechnik AG / Miscellaneous
Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.
----------------------------------------------------------------------
Berlin, 30 April 2008. On the occasion of its tenth anniversary, the
Berlin-based company Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN
DE 0005659700) announced that it will be offering 25 travel grants for the
annual congresses of the European Association of Nuclear Medicine (EANM).
These grants are designed to support young scientists and doctoral students
throughout Europe who seek to present the results of their work directly to
larger audiences over the next five years. The winners will be selected
together with EANM, starting with the annual European congress in Munich in
October of 2008.
In the words of Eckert & Ziegler CEO Dr. Andreas Eckert, 'With the 'EANM
Eckert & Ziegler Abstract Award', we want to encourage young researchers to
present their ideas to larger audiences and to engage in more intensive
exchange with specialists in nuclear medicine. Our hope is to support the
process whereby the enormous advances being made in medical imaging can
soon be turned into more precise, rapid and economical diagnostic and
treatment procedures.'
The Group sees considerable potential in the further development of nuclear
medical diagnostic techniques, especially based on more widespread use of
so-called hybrid cameras. These cameras combine different imaging processes
– including Positron Emission Topography, a nuclear medical method also
known as PET scans. The quality and information content of the images are
taking on completely new dimensions and are enabling the development of new
treatments and operational control processes.
Eckert & Ziegler is supporting greater use of hybrid systems by expanding
its production sites for radioactive contrast agents, and by developing
automated synthesis modules in which scientists can produce new diagnostic
substances with the requisite pharmaceutical quality. The Group, which
currently has around 450 employees and expects sales of 70 million euros in
2008, is one of the world's largest providers of isotope component
technology for radiation therapy and nuclear medicine.
The Board
Your contact:
Eckert & Ziegler AG
Thomas Scheuch, Investor Relations, Robert-Rössle-Str. 10, D-13125 Berlin
phone: +49 (0) 30 / 941084-139, fax-112, e-mail: thomas.scheuch@ezag.de,
www.ezag.de
30.04.2008 Financial News transmitted by DGAP
----------------------------------------------------------------------
Language: English
Issuer: ECKERT & ZIEGLER Strahlen- und Medizintechnik AG
Robert-Rössle-Str. 10
13125 Berlin
Deutschland
Phone: +49 (0)30 941 084-0
Fax: +49 (0)30 941 084-112
E-mail: thomas.scheuch@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, München, Hamburg, Düsseldorf
End of News DGAP News-Service
---------------------------------------------------------------------------